Tag Archives: type 2 diabetes treatment

Depression and Diabetes. Diabetic Complications

Men and women in whom both diabetes mellitus and depression are likely to develop are usually struggling with obesity, smoke cigarettes, and have inactive ‘couch potato’ lifestyle. These people are in risk group for coronary artery disease because of elevatec C-reactive protein levels.
Although depression often precedes the onset of type 2 diabetes by 6 to 8 years, people with mental illness are at high risk for developing diabetes disease and ling-term diabetic complications including macrovascular disease and microvascular disease. » Read more

Share This:

Meglitinides for Type 2 Diabetes Treatment. Oral Diabetic Medications

Meglitinides drug class for Type 2 diabetes treatment include repaglinide (Prandin) and nateglinide (Starlix) as oral diabetic medications. High fasting insulin levels and a reduction in insulin action may be present in person with Type 2 diabetes symptoms but so is absent or blunted first-phase insulin response to a meal. Most sulfonylureas (except Amaryl glimepiride) increase pancreatic beta-cell insulin secretion as well as plasma insulin concentration in people with Type 2 diabetes symptoms. But sulfonylureas oral diabetic medications fail to improve first-phase insulin release. Here comes meglitinides for Type 2 diabetes treatment. Starlix (nateglinide) and Prandin (repaglinide) as oral diabetic medications do increase first-phase insulin response, allowing to control sugar levels in blood after a meal. Both Starlix 60 mg pills and Prandin 1 mg pills are rapid-acting insulin secretagogues. When Prandin or Starlix meglitinides are taken 15 to 20 minutes before a meal, postprandial glucose excersions can be contained and minimized by this oral diabetic medications. This is important because high glucose level after a meal has been linked to cardiovascular diabetic complication.

» Read more

Share This:

Diabetic Nephropathy. Diabetic Kidney Disease. Diabetic Complications

Diabetic nephropathy is one of the microvascular complications of diabetes disease. Diabetic complications are causing most death in patients with diabetes disease. Diabetic nephropathy is a diabetic kidney disease. Diabetic nephropathy is characterized by following symptoms: progressive kidney failure, hypertension (high blood pressure), and proteinuria.

» Read more

Share This:

Dipeptidyl Peptidase IV Inhibitor. Januvia Sitagliptin in Type 2 Diabetes Treatment

There is considerable interest in the dipeptidyl peptidase IV (DPP-IV) medications for type 2 diabetes treatment because, as a class, dipeptidyl peptidase IV drugs such as Januvia 25 mg pills (sitagliptin) appear to be well tolerated by people on type 2 diabetes treatment and can be used efficiently as monotherapy or as combination therapy together with Metformin (Glucophage, Fortamet, Glumetza drugs) oral diabetic medications. Beneficial effects of Januvia (sitagliptin) and dipeptidyl peptidase IV inhibitors as class on the pancreas beta-cell function raise the possibility that these sitagliptin agents of DPP-IV inhibitors may be able to modify the natural history of type 2 diabetes, given that Januvia used in proper type 2 diabetes treatment plan.

» Read more

Share This:

Pramlintide (Symlin) for Type 1 Diabetes Treatment and Type 2 Diabetes Treatment

One of the most frustrating side effects associated with overall blood glucose control improvement in people with diabetes using intensive insulin therapy is weight gain. The addition of Symlin (pramlintide) to intensive insulin therapy for diabetes treatment improves long-term blood glucose control beyond that obtained with insulin therapy alone and significantly decreases weight gain and risk of hypoglycemia events. Pramlintide (Symlin) is an analogue to the native amylin.

» Read more

Share This:

Exenatide in Combination Therapy. Type 2 Diabetes Treatment

 Bydureon exenatide or Byetta exenatide are novel GLP-1 (Glucagon-like Peptide-1) incretin mimetic hormone FDA approved for use in type 2 diabetes treatment. Byetta (exenatide) and Bydureon (exenatide) are used in combination therapy to improve blood glucose control in people diagnosed with type 2 diabetes who are taking sulfonylureas, a metformin, a thiazolidinediones (TZDs), a combination of metformin and thiazolidinediones, or a combination of sulfonylureas and metformin.

» Read more

Share This:

Inhaled Pulmonary Insulin for Type 2 Diabetes Treatment

Current widely accepted game plan for type two diabetes treatment suggest that lifestyle changes be initially prescribed including diabetic diet, followed by initiation of monotherapy with type 2 diabetes medications, followed by combination therapy (perhaps with exenatide drug Bydureon or Byetta), and ultimately by insulin regimen. It is common knowledge that every person with Type 2 diabetes will eventually need insulin therapy no matter how well it adhere to type 2 diabetes treatment with oral medications or diabetic diet.

» Read more

Share This:

Type 2 Diabetes Medications. Sulfonylureas Medications for Type 2 Diabetes Treatment

Sulfonylureas medications for Type 2 diabetes treatment were first type two medications marketed in 1957 for type 2 diabetes treatment. The first generation sulfonylureas which are tolinase, diabinese, and orinase, can improve hyperglycemia but potential drug interactions resulting in hypoglycemia make these type 2 diabetes medications less attractive than the following second generation of sulfonylureas drugs. Glipizide and glyburide drugs were introduced in 1984, with glimepiride followed in 1996.
» Read more

Share This:

Exenatide (Byetta) for Type 2 Diabetes Treatment

Exenatide drug under brand Byetta is a novel GPL-1 (Glucagon-like Peptide-1) incretin mimetic hormone that has been FDA approved for use in poorly managed Type 2 diabetes individuals using sulfonylureas and metformin pills. Glucagon-like Peptide-1 is secreted from enteroendocrine cells located in the ileum and colon in response to a meal. People with Type 2 sugar diabetes and impaired glucose tolerance are GPL-1 (glucagon-like Peptide-1) deficient. When given before a meal, exenatide (Byetta) restores first-phase insulin response in people with Type 2 diabetes. Exenatide reduces postprandial glucagon levels and increases insulin release from the beta cells. Exenatide (Byetta) injections improve gastric emptying and promotes satiety. It is noted that Byetta (exenatide) appears to reduce beta-cell death (apoptosis). Exenatide (Byetta) functions in a glucose-dependent fashion which means that the effects of the exenatide drug are obvious mainly in the presence of hyperglycemia. You can buy exenatide drug Byetta online now from various vendors following selected links to the right.

» Read more

Share This:

Glucagon Like Peptide 1 Incretin Hormone. What is Glucagon Like Peptide 1?

Excessive food intake in patients with diabetes disease who are unable to reach normal body blood sugar level is thought to result in the production of incretin-antagonist hormones, leading to glucose intolerance and dysregulated insulin production in the pancreas. How to control blood sugar level. To control sugar level in blood body need to produce enough insulin to utilize excessive sugar. What is glucagon like peptide 1? Incretin hormones, such as glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide are hormones released from the small intestines in response to ingested food. Control of blood glucose levels works through join forces of insulin and glucagon like peptide 1 hormones.

» Read more

Share This: